bacillus subtilis + enterococcus faecium + bortezomib + dexamethasone + daratumumab

This is a combination regimen consisting of two probiotic bacterial strains (Bacillus subtilis and Enterococcus faecium), the proteasome inhibitor bortezomib, the synthetic glucocorticoid dexamethasone, and the anti-CD38 monoclonal antibody daratumumab. - **Bacillus subtilis** and **Enterococcus faecium** are live biotherapeutic products commonly used as probiotics to modulate gut microbiota and support gastrointestinal health. - **Bortezomib** is a small molecule proteasome inhibitor that disrupts protein degradation in cells, leading to apoptosis in malignant plasma cells; it is primarily used for multiple myeloma treatment. - **Dexamethasone** is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressive properties, often used in cancer regimens to reduce inflammation or as part of chemotherapy protocols[1][2][3][4][5]. - **Daratumumab** is a human monoclonal antibody targeting CD38 on plasma cells, inducing cell death via immune-mediated mechanisms; it is approved for use in multiple myeloma. This combination may be considered investigational or off-label if all five components are administered together, as there are no widely recognized fixed-dose combinations containing these exact ingredients.